FIRMS REQUESTING PRE-SUBMISSION MEETINGS SPECIFIED IN HOUSE FDA REFORM BILL MUST PROVIDE DETAILED PROTOCOLS; CDRH PREPARING FOR IMPLEMENTATION OF LEGISLATION
This article was originally published in The Gray Sheet
Executive Summary
Sponsors of premarket approval applications seeking a pre-submission meeting to gain feedback on clinical trial protocols must provide the agency with a detailed outline of proposed studies and background on company attendees at the meeting, according to the House Commerce Committee's Oct. 6 report on the stand-alone FDA device reform bill (HR 1710).
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.